Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-03 - Q4 2024 Earnings Release (Projected)

More about the company

Capitalization	5.64M 5.37M 4.97M 4.42M 7.99M 478M 8.85M 61.93M 22.86M 196M 21.17M 20.71M 857M	P/E ratio 2022	-1.09x	P/E ratio 2023	-0.09x
Enterprise value	124K 118K 110K 97.64K 176K 10.56M 195K 1.37M 505K 4.34M 467K 457K 18.92M	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site	Oct. 10	CI
Clearmind Medicine Inc. Approves the Appointment of Hila Kiron-Revach to Its Board	Sep. 26	CI
Clearmind Applies for Patent on Anti-Addiction Combination Therapy -- Shares Up After Hours	Sep. 16	MT
Scisparc Ltd. and Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy	Sep. 16	CI
Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy	Sep. 16	CI
Clearmind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024	Sep. 16	CI
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment	Sep. 06	CI
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines	Sep. 06	CI
SciSparc -Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination	Aug. 29	CI
Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment	Aug. 29	CI
Clearmind Medicine Gets Patent Approval for Proprietary Binge Behavior Regulator Program	Aug. 21	MT
Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment	Aug. 21	CI
Clearmind Medicine Inc. and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders	Aug. 16	CI

CLEARMIND MEDICINE : MANAGEMENT INFORMATION CIRCULAR Form 6 K	Dec. 06	PU
Clearmind Medicine : Notice of Annual and Special Meeting of Shareholders of Clearmind Medicine Inc. to be held on January 6, 2024 Form 6 K	Nov. 20	PU
Clearmind Medicine : FDA approval for the IND submission to conduct its trial already secured Form 6 K	Oct. 10	PU
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site	Oct. 10	AQ
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy	Sep. 16	AQ

Director	Title	Age	Since
Adi Zuloff-Shani CEO	Chief Executive Officer	54	2021-07-13
Alan Rootenberg DFI	Director of Finance/CFO	72	2022-06-13
Mark Haden PRN	Corporate Officer/Principal	70	2021-06-30

Manager	Title	Age	Since
Amitay Weiss CHM	Chairman	62	2019-08-18
Yehonatan Shachar BRD	Director/Board Member	33	2020-04-14
Oz Adler BRD	Director/Board Member	36	2021-09-20

Clearmind Medicine Inc. Stock Canadian Securities Exchange

Equities

CMND

CA1850534027

Biotechnology & Medical Research

Valuation: Clearmind Medicine Inc.

Chart: Clearmind Medicine Inc.

Latest news: Clearmind Medicine Inc.

Press Releases: Clearmind Medicine Inc.

Managers and Directors: Clearmind Medicine Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
LONZA GROUP AG	-0.88%	-1.82%	+59.63%	-30.10%	42.84B
IQVIA HOLDINGS INC.	-1.57%	+1.31%	-5.61%	-24.83%	36.88B
CELLTRION, INC.	+4.00%	-2.57%	+8.59%	-7.13%	26.23B
ICON PUBLIC LIMITED COMPANY	-1.49%	+1.39%	-20.74%	-22.06%	17.83B
MODERNA, INC.	-9.07%	-2.51%	-48.32%	-83.85%	15.97B
UNITED THERAPEUTICS CORPORATION	-1.30%	-1.78%	+49.90%	+92.10%	16.17B
BIO-TECHNE CORPORATION	-0.36%	+2.76%	+12.90%	-33.81%	12.25B
MEDPACE HOLDINGS, INC.	-2.92%	+0.79%	+20.75%	+67.08%	10.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.33%	-1.13%	-3.62%	-44.92%	10.08B
Average	-1.77%	+0.15%	+8.16%	-9.72%	20.98B
Weighted average by Cap.	-1.29%	+0.11%	+13.66%	-14.78%

	2022	2023
Net sales	-	-
Net income	-9.41M -8.96M -8.3M -7.38M -13.33M -799M -14.77M -103M -38.16M -328M -35.33M -34.57M -1.43B	-8.62M -8.21M -7.6M -6.76M -12.21M -732M -13.53M -94.68M -34.95M -300M -32.37M -31.67M -1.31B
Net Debt	-388K -369K -342K -304K -549K -32.91M -609K -4.26M -1.57M -13.51M -1.46M -1.42M -58.97M	-5.51M -5.25M -4.86M -4.33M -7.81M -468M -8.65M -60.56M -22.36M -192M -20.7M -20.25M -838M